A
Antabio
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO
About Antabio
Operator of a private European biopharmaceutical company intended to develop novel and highly differentiated antibacterial treatments. The company's resistance-breakers develop stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens, enabling health professionals to get access to medicinal products that help in curing drug-resistant diseases. Keywords: Pharmaceuticals and Biotechnology, Antiinfective Product, Antimicrobial Resistance, Antimicrobial Resistance Treatment, Carbapenem-Resistant, Chronic Pulmonary, Drug Development, Nosocomial Infectious Disease, Nosocomial Pneumonia, Pseudomonas Aeruginosa.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Labège, France
- Employees
- 25
- Open positions
- 1
- Dealroom signal
- 81.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Bacteria, Molecular, Sustainable Development Goals, EIC, Biotech and Pharma, EIC Fund, biotech medtech and e-health
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2022
- Capital deployed
- $9M
- Preferred round
- EARLY VC
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2023 | $28M | $110M | Irdi Capital Investissement · Turenne Capital · BNP Paribas Développement · AMR Action Fund | ↗ |
| CONVERTIBLEOther financing | Jun 2023 | $3.3M | — | EIC Fund | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Antabio is 1.7K monthly website visits, up 41.7% over the last three months. Antabio's team grew 4.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
- BPBusiness Angel Pool
Wellcome Trust
CARB-X
European Innovation Council
Series A8 investors entered at this stage
iXO Private Equity
BNP Paribas Développement
Irdi Capital Investissement
Turenne Capital
Omnes Capital
Galia Gestion
EIC Fund
AMR Action Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antabio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antabio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.